undamentalytics Newsletter
Sign in

Usana Health Sciences Inc (USNA) stock

Add to watchlist

Add holding +

NYSE: USNA NYSE Personal Care Products Next results ~November 3, 2026

C Fundamentals grade

Usana Health Sciences Inc is a US-listed company in the personal care products industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$51

Cash-flow model

Base case. Range ~$40–$65 across our lower- and higher-growth cases (-3%–7% a year).

Price vs value

Undervalued

The price is below our entire value range; our base value is 245% above it.

Price used: $14.72, November 2, 2026

Usana Health Sciences Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 9 selling0 purchases and 16 sales by directors and officers, last 12 monthsInsider trades
  • Funds82 adding, 50 cuttingOf 27 active managers that changed their stake, 13 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Usana Health Sciences files

Where Usana Health Sciences stands after its latest 10-Q

Revenue for the twelve months to July 2026 was $913m, up 1.6% on a year earlier, slower than the 5.7% growth a quarter earlier. Free-cash-flow margin fell to 1.7% from 5.7% a year earlier. Operating margin narrowed to -0.1% from 6.2%. The diluted share count is down 2.9% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 3 financial-health checks. Our cash-flow model value is $49.48 a share, against a share price of $14.47.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Usana Health Sciences Inc's trailing-twelve-month revenue grew 1.6% year on year, with a free-cash-flow margin of 1.7%. Where it stands out: gross margin of 77.4% ranks 3 of 21 personal care products companies we cover. Where it lags: change in growth rate of -4.1pp ranks 19 of 21 personal care products companies we cover.

Our discounted-cash-flow model values the business at ~$51 per share in the base case (~$40–$65 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Gross margin compressing: TTM gross margin fell to 77.4%, down 2.5pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Priced below our value. The share price of $14.72 is 245% below our value per share of $51.
  • Shrinking share count. Diluted shares fell 2.9% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.2bn.

Things to watch

  • Loss-making. Operating margin is -0.1%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 6.4 points on a year ago.
  • Volatile shares. Over the past year the shares showed annualised volatility of 53% and a beta of 0.9 against the S&P 500.
  • Growth easing. The growth rate is 4.1 points lower than a quarter earlier.
  • Gross margin slipping. Gross margin is down 2.5 points on a year ago.
  • Below peers: change in growth rate. Change in growth rate of -4.1pp ranks 19 of 21 personal care products companies we cover (median +0.7pp).

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$0.07 against an average estimate of $0.43: missed by 116.3%
Revenue
$223m, down 5.3% on a year earlier
Share reaction
-34.4% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Next report
November 3, 2026; average EPS estimate $0.11

Usana Health Sciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.9%
  • 1 week+4.8%
  • 1 month-0.7%
  • This year-25.0%
  • 1 year-30.4%
  • 5 years-85.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$913M
Operating margin
-0.1%
Net margin
-2.4%
EPS (TTM, diluted)
$-1.21

Growth

Revenue growth
+1.6%
Change in growth rate
−4.1 pts
Share count change
−2.9%

Cash

Free cash flow (TTM)
$15.9M
FCF margin
1.7%
Stock pay % of revenue
1.6%

Earnings

Last results
August 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Usana Health Sciences Inc valuation models and calculator

What the price is pricing in

The share price implies cash flow shrinking about 26.9% a year for five years.That is slower than the -5.1% a year revenue growth Usana Health Sciences has delivered.

Read with care: free cash flow has swung sharply in the past year (often a one-off tax, legal or working-capital item), so the cash-flow base behind this reading may be unusually low or high.

  • Priced in-26.9%
  • Last 12 months1.6%
  • 3 years a year-1.2%
  • 5 years a year-5.1%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($14.89, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Buy12-month view
12-month price target
~$51
Price used
$14.89close November 3, 2026
Implied change
▲ +241%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Usana Health Sciences Inc's free cash flow after stock-based pay with after-tax interest added back ($48.9M, FY2026 Q2 TTM), growing 1.7% and 2.3% in the next two years (forecasts, guidance and its record), then back to 2% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$40–~$65 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Usana Health Sciences Inc's free cash flow after stock-based pay ( $48.9M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Usana Health Sciences Inc as an operating company, with every model that fits that kind of business. Cost of equity 7.8%: the 10-year Treasury yield (4.9%) plus a beta of 0.64 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$51 ~$40–$65 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$39 ~$25–$64 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$41 ~$34–$52 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$46 ~$39–$51 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Usana Health Sciences Inc with Personal Care Products in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −17%
  • Revenue growth 5 points higher ▲ +23%
  • Free-cash-flow margin 1 point lower ▼ −39%
  • Last year's free-cash-flow margin change, if it persists ▼ −60%
  • Discount rate 1 point higher ▼ −10%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $45$59$77$101$132$172
8.5% $36$46$59$76$98$127
10% $31$38$48$61$78$100

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$63.88$61.20$74.05$114.96$80.00$77.10$101.20$53.20$53.60$35.69$19.44$14.72
Market value$1.7bn$1.5bn$1.8bn$2.8bn$1.8bn$1.6bn$2.1bn$1.0bn$1.0bn$684m$361m$271m
+ Net debt (− = net cash)−$143m−$176m−$247m−$214m−$235m−$312m−$240m−$288m−$330m−$159m−$144m−$169m
Enterprise value$1.5bn$1.4bn$1.6bn$2.6bn$1.6bn$1.3bn$1.8bn$739m$707m$525m$217m$102m
Multiples
Price / sales 1.8x1.5x1.7x2.4x1.7x1.4x1.7x1.0x1.1x0.8x0.4x0.3x
Price / earnings 17.8x15.3x29.3x22.4x18.2x13.1x17.7x14.8x16.3x16.3x33.6x—
Price / free cash flow 19.2x14.7x16.5x20.1x16.6x11.3x19.0x11.0x18.5x13.4x42.4x17.0x
EV / EBITDA 10.2x8.9x10.6x12.8x9.9x7.0x9.9x6.1x6.7x6.5x3.1x3.3x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

72 /100

Strong moat

How hard Usana Health Sciences's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Net income has been a median 15.0% of total assets over 10 years.

  • Pricing power 20 / 20

    Gross margin has been a median 81.4%, moving by 1.6 percentage points (standard deviation) across 10 years.

  • Durability 3 / 20

    Operating margin has been a median 12.8%; its worst year was -0.1%.

  • Cash conversion 14 / 20

    Free cash flow was positive in 10 of 10 years, at a median 8.8% of revenue.

  • Discipline 20 / 20

    The diluted share count fell 12.3% over five years; stock-based pay has been a median 1.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (78 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $217m and EPS of $0.11 (range $0.11 to $0.11) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.76 −61% $909m −2%
Next $1.77 +133% $945m +4%

Next year's EPS estimate has moved −36.1% in 90 days, across 1 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −64.2% on 90 days ago. In the last 30 days, 0 analysts raised Usana Health Sciences Inc's forecast and 1 cut it.

Consensus EPS forecast Usana Health Sciences Inc, last 90 days
$0.00 $1.00 $2.00 $3.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $2.12 Current fiscal year, 60 days ago: $0.76 Current fiscal year, 30 days ago: $0.76 Current fiscal year, 7 days ago: $0.76 Current fiscal year, Now: $0.76 $0.76 Next fiscal year, 90 days ago: $2.77 Next fiscal year, 60 days ago: $1.77 Next fiscal year, 30 days ago: $1.77 Next fiscal year, 7 days ago: $1.77 Next fiscal year, Now: $1.77 $1.77

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $2.12$2.77
60 days ago $0.76$1.77
30 days ago $0.76$1.77
7 days ago $0.76$1.77
Now $0.76$1.77

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.43 −$0.07 −116.3%
Mar 2026 $0.44 $0.61 +38.6%
Dec 2025 $0.41 $0.60 +46.3%
Sept 2025 −$0.15 −$0.15 0.0%

Adjusted EPS as companies report it, against the average analyst estimate.

How our valuation uses these forecasts

Our cash-flow model grows Usana Health Sciences Inc's revenue by +1.7% next year and +2.3% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+1.4%, weight 45%) and the company's own record (+2.0%, weight 55%) . How the weights are set.

Positioning

Short interest
7.1%
of tradable shares
Days to cover
4.28
at average volume
Short interest, 1 month
+3%
to October 15, 2026
Held by institutions
63%
of shares
Held by insiders
40.9%
of shares
Employees
1,570
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months −30.4%

$21.15 on October 31, 2025 to $14.72

ThenNowEffect
Revenue (last 12 months) $899m $913m +1.6%
P/S multiple 0.4x 0.3x −33.5%
Share count 19m 18m +3.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −68.2%

$46.34 on November 3, 2023 to $14.72

ThenNowEffect
Revenue (last 12 months) $948m $913m −3.6%
P/S multiple 0.9x 0.3x −68.6%
Share count 19m 18m +5.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
USNA+31%−47%+1%−33%−45%−25%
Industry peers (median)+31%−32%+6%−8%−34%+1%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
USNA67%17%67%33%33%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
USNA−18%−53%−35%−39%−49%−45%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 91% from July 25, 2018 to August 17, 2026. Getting back needed a 960% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$12.86 – $23.24
From 52-week high
−36.7%
vs 50-day average
+1.0%
vs 200-day average
−18.5%
Volatility (1 year)
53%
Beta vs S&P 500
0.87

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±9.2%
After a week
5 up, 7 down
typical move ±10.8%
After a month
5 up, 7 down
typical move ±15.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 −34.4% +1.6% −39.8% −36.3%
May 5, 2026 +7.8% +2.2% −6.5% −2.3%
February 18, 2026 −0.5% +0.2% +2.9% −17.0%
January 12, 2026 +2.3% 0.0% +10.7% +6.5%
October 22, 2025 −1.9% +0.1% −6.8% −11.2%
October 9, 2025 −23.6% −3.0% −20.5% −27.8%
July 22, 2025 +17.0% +0.9% −0.1% +2.7%
April 22, 2025 +6.7% +4.2% +17.0% +24.9%
February 25, 2025 +1.6% −0.4% −9.5% −16.7%
October 22, 2024 +4.4% −1.0% +6.4% +12.8%
July 23, 2024 −3.7% −2.4% −5.3% −13.6%
April 30, 2024 +6.0% −1.9% +4.1% +8.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Usana Health Sciences Inc’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: fundamentals grade C (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: the shares trade below our fair value: a collar caps upside the model expects.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Usana Health Sciences Inc in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Usana Health Sciences Inc
$840M $860M $880M $900M $920M $940M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $927.9M Revenue (TTM), FY23 Q4: $921M Revenue (TTM), FY24 Q1: $900.5M Revenue (TTM), FY24 Q2: $875.1M Revenue (TTM), FY24 Q3: $862M Revenue (TTM), FY24 Q4: $854.5M Revenue (TTM), FY25 Q1: $876.2M Revenue (TTM), FY25 Q2: $899.2M Revenue (TTM), FY25 Q3: $912.7M Revenue (TTM), FY25 Q4: $925.3M Revenue (TTM), FY26 Q1: $925.9M Revenue (TTM), FY26 Q2: $913.4M $913.4M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $927.9M
FY23 Q4 $921M
FY24 Q1 $900.5M
FY24 Q2 $875.1M
FY24 Q3 $862M
FY24 Q4 $854.5M
FY25 Q1 $876.2M
FY25 Q2 $899.2M
FY25 Q3 $912.7M
FY25 Q4 $925.3M
FY26 Q1 $925.9M
FY26 Q2 $913.4M
Revenue growth, TTM YoY Usana Health Sciences Inc
-15% -10% -5% 0% 5% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -10.6% Revenue growth, TTM YoY, FY23 Q4: -7.8% Revenue growth, TTM YoY, FY24 Q1: -7.6% Revenue growth, TTM YoY, FY24 Q2: -7.7% Revenue growth, TTM YoY, FY24 Q3: -7.1% Revenue growth, TTM YoY, FY24 Q4: -7.2% Revenue growth, TTM YoY, FY25 Q1: -2.7% Revenue growth, TTM YoY, FY25 Q2: 2.8% Revenue growth, TTM YoY, FY25 Q3: 5.9% Revenue growth, TTM YoY, FY25 Q4: 8.3% Revenue growth, TTM YoY, FY26 Q1: 5.7% Revenue growth, TTM YoY, FY26 Q2: 1.6% 1.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -10.6%
FY23 Q4 -7.8%
FY24 Q1 -7.6%
FY24 Q2 -7.7%
FY24 Q3 -7.1%
FY24 Q4 -7.2%
FY25 Q1 -2.7%
FY25 Q2 2.8%
FY25 Q3 5.9%
FY25 Q4 8.3%
FY26 Q1 5.7%
FY26 Q2 1.6%
Operating margin (TTM) Usana Health Sciences Inc
-5% 0% 5% 10% 15% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 9.9% Operating margin (TTM), FY23 Q4: 10.1% Operating margin (TTM), FY24 Q1: 10.1% Operating margin (TTM), FY24 Q2: 9.6% Operating margin (TTM), FY24 Q3: 9.6% Operating margin (TTM), FY24 Q4: 7.8% Operating margin (TTM), FY25 Q1: 6.5% Operating margin (TTM), FY25 Q2: 6.2% Operating margin (TTM), FY25 Q3: 4.6% Operating margin (TTM), FY25 Q4: 4.0% Operating margin (TTM), FY26 Q1: 3.8% Operating margin (TTM), FY26 Q2: -0.1% -0.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 9.9%
FY23 Q4 10.1%
FY24 Q1 10.1%
FY24 Q2 9.6%
FY24 Q3 9.6%
FY24 Q4 7.8%
FY25 Q1 6.5%
FY25 Q2 6.2%
FY25 Q3 4.6%
FY25 Q4 4.0%
FY26 Q1 3.8%
FY26 Q2 -0.1%
FCF margin (TTM) Usana Health Sciences Inc
0% 5% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 8.0% FCF margin (TTM), FY23 Q4: 6.1% FCF margin (TTM), FY24 Q1: 6.7% FCF margin (TTM), FY24 Q2: 6.8% FCF margin (TTM), FY24 Q3: 7.6% FCF margin (TTM), FY24 Q4: 6.0% FCF margin (TTM), FY25 Q1: 5.6% FCF margin (TTM), FY25 Q2: 5.7% FCF margin (TTM), FY25 Q3: 2.0% FCF margin (TTM), FY25 Q4: 0.9% FCF margin (TTM), FY26 Q1: 0.3% FCF margin (TTM), FY26 Q2: 1.7% 1.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 8.0%
FY23 Q4 6.1%
FY24 Q1 6.7%
FY24 Q2 6.8%
FY24 Q3 7.6%
FY24 Q4 6.0%
FY25 Q1 5.6%
FY25 Q2 5.7%
FY25 Q3 2.0%
FY25 Q4 0.9%
FY26 Q1 0.3%
FY26 Q2 1.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Usana Health Sciences took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $925M
  2. Cost of revenue $201M · 21.7%
  3. Gross profit $724M · 78.3%
  4. Research and development $10.7M · 1.2%
  5. Selling, general and admin $337M · 36.5%
  6. Other operating costs $339M · 36.6%
  7. Operating income $37.4M · 4.0%
  8. Income tax $30.1M · 3.2%
  9. Net income $10.8M · 1.2%

Shares of revenue. Source: Usana Health Sciences's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Jan 2010 2010 Jan 2011 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Jan 2015 2015 Jan 2016 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Jan 2021 2021 Jan 2022 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Jan 2026 LTM Jul 2026
Income
Revenue 437 518 582 649 718 790 918 1,006 1,047 1,189 1,061 1,135 1,186 999 921 855 925 913
Gross profit 347 422 480 533 591 650 759 826 868 989 873 926 969 805 744 693 724 707
EBITDA 58 76 86 107 126 125 152 152 149 205 161 190 183 121 106 81 70 31
Operating income 51 68 77 98 117 116 142 139 133 188 146 176 170 108 93 66 37 −1
Net income 34 46 51 66 79 77 95 100 63 126 101 125 117 69 64 42 11 −22
Diluted EPS $1.08 $1.43 $1.63 $2.23 $2.78 $2.80 $3.59 $3.99 $2.53 $5.12 $4.41 $5.86 $5.73 $3.59 $3.30 $2.19 $0.58 −$1.21
Growth (year on year)
Revenue — +18.5% +12.4% +11.5% +10.7% +10.1% +16.2% +9.5% +4.1% +13.6% −10.8% +7.0% +4.6% −15.8% −7.8% −7.2% +8.3% +1.6%
EBITDA — +31.6% +12.6% +24.8% +17.5% −0.7% +21.4% +0.3% −2.3% +38.1% −21.6% +18.2% −3.7% −34.0% −12.6% −23.6% −13.4% −60.7%
Operating income — +34.3% +13.3% +27.1% +18.9% −0.5% +22.0% −2.1% −4.4% +42.1% −22.4% +20.7% −3.6% −36.8% −13.5% −28.7% −43.6% −101.9%
Net income — +36.0% +11.2% +30.9% +19.0% −3.0% +23.5% +5.7% −37.5% +101.8% −20.4% +24.0% −6.5% −40.5% −8.0% −34.1% −74.4% −165.0%
Diluted EPS — +31.8% +14.0% +36.5% +24.9% +0.7% +28.2% +11.1% −36.6% +102.4% −13.9% +32.9% −2.2% −37.3% −8.1% −33.6% −73.5% −166.9%
Margins
Gross margin 79.4% 81.6% 82.5% 82.1% 82.3% 82.2% 82.6% 82.1% 82.9% 83.1% 82.3% 81.6% 81.6% 80.6% 80.8% 81.1% 78.3% 77.4%
EBITDA margin 13.2% 14.7% 14.7% 16.5% 17.5% 15.8% 16.5% 15.1% 14.2% 17.3% 15.2% 16.8% 15.4% 12.1% 11.5% 9.5% 7.6% 3.4%
Operating margin 11.6% 13.2% 13.3% 15.1% 16.3% 14.7% 15.4% 13.8% 12.7% 15.8% 13.8% 15.6% 14.3% 10.8% 10.1% 7.8% 4.0% −0.1%
Net margin 7.7% 8.8% 8.7% 10.2% 11.0% 9.7% 10.3% 9.9% 6.0% 10.6% 9.5% 11.0% 9.8% 6.9% 6.9% 4.9% 1.2% −2.4%
Free-cash-flow margin 6.5% 12.0% 10.2% 13.0% 12.6% 10.7% 9.6% 10.4% 10.6% 11.8% 10.4% 12.8% 9.1% 9.4% 6.1% 6.0% 0.9% 1.7%
Cash flow
Cash from operations 32 66 70 93 99 105 111 137 124 152 127 160 121 104 71 61 22 28
Capital spending 4 4 11 8 8 20 24 33 13 11 17 15 13 10 14 10 14 12
Free cash flow 28 62 59 84 91 85 88 104 111 141 110 145 108 94 56 51 9 16
Stock-based pay 9 10 11 10 8 10 11 17 15 15 16 14 14 13 15 15 14 14
Free cash flow after stock pay 19 52 49 74 83 75 77 88 95 126 95 131 94 80 42 36 −5 2
Balance sheet
Cash 14 50 50 71 137 111 143 176 247 214 235 312 240 288 330 182 158 169
Total debt 0 0 0 0 0 0 0 — 0 0 0 0 0 0 1 23 14 0
Net debt (negative = net cash) −14 −50 −50 −71 −137 −111 −143 −176 −247 −214 −235 −312 −240 −288 −330 −159 −144 −169
Diluted shares 31m 32m 31m 30m 28m 27m 26m 25m 25m 25m 23m 21m 20m 19m 19m 19m 19m 18m
Returned to shareholders
Buybacks 2 17 33 68 18 139 61 65 50 105 150 57 178 25 12 9 28 0
Total returned 2 17 33 68 18 139 61 65 50 105 150 57 178 25 12 9 28 0

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · July 4, 2026
What it owns · $703m
Short-term assets $281mLonger-term assets $422m
What it owes, and who funded it · $659m
Short-term liabilities $106mLonger-term liabilities $27mShareholders' equity $526m
  • Short-term assets cover short-term liabilities $281m of assets due within a year against $106m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $281m short-term assets against $27m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$1m against $412,000 of interest.

From Usana Health Sciences Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$0
Returned to shareholders
0%
of free cash flow
Buybacks, last 3 fiscal years
$48.5M
Diluted share count
−2.9%
year over year
Total shareholder yield
0.0%
dividends 0.0% + buybacks 0.0% of market value
Sales & admin spending
36.6%
of revenue

Competitors: side by side with peers

Closest by revenue in personal care products
Last 12 months unless stated USNA ODD NUS IPAR NATR ELF Median
Revenue, last 12 months $913m $810m $1.4bn $1.5bn $492m $1.8bn $913m
Revenue growth, last 12 months 1.6% 25.2% −15.4% 2.9% 6.8% 31.2% 3.5%
Revenue growth, 3-year average −1.2% — −12.3% 7.4% 4.4% 37.9% −0.1%
Revenue growth, latest quarter −5.3% — −17.1% 2.1% 1.9% 35.5% 2.7%
Gross margin 77.4% 72.7% 69.2% 63.8% 73.2% 74.4% 69.2%
Operating margin −0.1% 14.7% −0.8% 17.3% 6.0% 7.2% 6.7%
Operating margin, 3-year average 5.3% — −2.8% 17.9% 5.1% 10.4% 5.5%
Net margin −2.4% 13.7% −15.7% 11.2% 3.7% 3.4% 3.4%
Cash from operations / revenue 3.0% 10.8% 3.7% 17.1% 5.6% 16.9% 9.9%
Free-cash-flow margin 1.7% 10.3% 0.8% 16.4% 3.7% 15.9% 9.6%
Free-cash-flow margin, 3-year average 4.7% — 3.4% 11.7% 4.0% 9.8% 6.0%
Stock pay / revenue 1.6% 4.2% 1.0% 0.1% 1.3% 5.5% 1.0%
Change in share count −2.9% — 0.1% −0.0% −4.6% 3.0% −0.0%

Median of all 21 companies we cover in personal care products. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

21 personal care products companies
Measure Company Peer median Rank
Revenue growth Growth 1.6% 3.5% 14 of 21
Change in growth rate Growth -4.1pp +0.7pp 19 of 21
Gross margin Profitability 77.4% 69.2% 3 of 21
Operating margin Profitability -0.1% 6.7% 16 of 21
Net margin Profitability -2.4% 3.4% 14 of 21
Free-cash-flow margin Cash generation 1.7% 9.6% 17 of 21
Stock pay as % of revenue Cash generation 1.6% 1.0% 13 of 18
Change in share count Balance sheet -2.9% -0.0% 6 of 19

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to January 3, 2026
Segments
Line of business Revenue Share YoY
Core Nutritional $775M 83.8% ▼ 8.3%
Hiya $132M 14.3% ▲ 6599.0%
All Other $17.8M 1.9% ▲ 164.4%
Geography
Region Revenue YoY
Asia Pacific $627M ▼ 8.2%
Greater China $425M ▼ 7.3%
China $382M ▼ 7.7%
Americas and Europe $298M ▲ 73.8%
United States $225M ▲ 145.0%
Southeast Asia Pacific $132M ▼ 10.1%
North Asia $70.6M ▼ 9.7%
South Korea $68.9M ▼ 9.9%

These categories overlap or exclude eliminations, so shares aren't shown.

From Usana Health Sciences Inc's 10-K filed March 16, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$261M
Institutions reporting
137
Shares held vs prior quarter
▲ 19.1%
Positions opened / closed
21 / 18

Top buyers and sellers, Q2 2026: 82 institutions bought and 50 sold ; the biggest buyer was Nantahala Capital Management, LLC (+810K shares) and the biggest seller Tudor Investment Corp Et Al (−70K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Nantahala Capital Management, LLC $34.6M 1.6M 13.2% ▲ 100.0%
Blackrock, Inc. $33.2M 1.6M 12.7% ▲ 30.6%
Pzena Investment Management LLC $25.7M 1.2M 9.9% ▲ 8.7%
Renaissance Technologies LLC $20.5M 959K 7.8% ▼ 5.8%
Dimensional Fund Advisors LP $17.9M 837K 6.8% ▲ 0.4%
Vanguard Capital Management LLC $10.4M 487K 4.0% ▲ 1.7%
Creative Planning $8.9M 418K 3.4% ▲ 116.4%
AQR Capital Management LLC $8.7M 408K 3.3% ▲ 37.7%
Vanguard Portfolio Management LLC $7.8M 363K 3.0% ▲ 7.4%
Geode Capital Management, LLC $6M 283K 2.3% ▲ 7.1%
Charles Schwab Investment Management Inc $5.8M 272K 2.2% ▼ 18.3%
State Street Corp $5.6M 261K 2.1% ▲ 5.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Usana Health Sciences Inc's complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $955,955 16 trades by 9 insiders · 0% under pre-set plans
Net ▼ $955,955 net selling
Insider Date Trade Shares Price Value
Neidig Brent CHIEF COMMERCIAL OFFICER June 16, 2026 Sell 5,002 $19.45 $97,289
Neidig Brent CHIEF COMMERCIAL OFFICER June 15, 2026 Sell 909 $20.01 $18,189
Neidig Brent CHIEF COMMERCIAL OFFICER June 12, 2026 Sell 1,602 $20.15 $32,280
Jones Paul A. CHIEF PEOPLE OFFICER June 8, 2026 Sell 5,561 $18.50 $102,878
Fleming John Turman Director June 1, 2026 Sell 2,450 $17.93 $43,928
Jones Paul A. CHIEF PEOPLE OFFICER May 28, 2026 Sell 6,813 $18.95 $129,106
Iiekking G Doug CHIEF FINANCIAL OFFICER May 27, 2026 Sell 5,360 $18.75 $100,500
Fuller Gilbert A Director May 22, 2026 Sell 1,057 $18.66 $19,724
Foukas Joshua CHIEF LEGAL OFFICER May 7, 2026 Sell 3,791 $19.82 $75,138
Fuller Gilbert A Director March 20, 2026 Sell 1,058 $17.00 $17,986
Benedict Peter CHIEF INFORMATION OFFICER March 3, 2026 Sell 4,553 $19.38 $88,237
Foukas Joshua CHIEF LEGAL OFFICER February 20, 2026 Sell 4,461 $21.35 $95,242

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 21, 2026 estimated from the company's past filing pattern, not announced

  • August 4, 2026
  • May 5, 2026
  • February 18, 2026
  • January 12, 2026
  • October 22, 2025
  • October 9, 2025

Recent SEC filings

Data status

When each part of this page on Usana Health Sciences Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Usana Health Sciences Inc in brief

What does Usana Health Sciences Inc do?
Usana Health Sciences Inc is a US-listed company in the personal care products industry. Its financial year ends in December.
What is Usana Health Sciences Inc's stock ticker?
Usana Health Sciences Inc trades under the ticker USNA on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Usana Health Sciences Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Usana Health Sciences Inc reported revenue of $913M, 1.6% higher than a year earlier, according to its SEC filings.
What is Usana Health Sciences Inc's free cash flow?
Usana Health Sciences Inc's free-cash-flow margin is 1.7% of revenue over the trailing twelve months, ranking 17 of the 21 personal care products companies we cover.
What is Usana Health Sciences Inc's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Usana Health Sciences Inc's free cash flow after stock-based pay gives ~$51 per share in the base case, and ~$40–$65 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Usana Health Sciences Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Nantahala Capital Management, LLC, Blackrock, Inc. and Pzena Investment Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Usana Health Sciences Inc buying back stock, and does it pay a dividend?
Usana Health Sciences Inc spent $0 on share repurchases over the trailing twelve months, and its diluted share count fell 2.9% over the year.
What is Usana Health Sciences Inc's market cap?
On November 2, 2026, Usana Health Sciences Inc's market capitalisation was about $271M and net debt of -$169M. Market figures come from third-party market data and may be delayed.
Who are Usana Health Sciences Inc's competitors?
In our Personal Care Products peer group, the companies closest to Usana Health Sciences Inc are Oddity Tech Ltd, NU Skin Enterprises, Inc., Interparfums Inc, Natures Sunshine Products Inc and E.l.f. Beauty, Inc. The side-by-side comparison below sets their revenue, margins and growth against Usana Health Sciences Inc's.
Are insiders buying or selling Usana Health Sciences Inc stock?
Over the last 12 months, Usana Health Sciences Inc's directors and officers reported 0 open-market purchases and 16 sales on Form 4. The insider trading page charts every trade.
When is Usana Health Sciences Inc's next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Usana Health Sciences Inc announces its own schedule.